From the National Organization for Rare Disorders (NORD):
On Jan. 4, the rare disease community celebrated the 40th anniversary of the Orphan Drug Act (ODA) — legislation that incentivized drug companies to put more resources toward the research, development, and distribution of therapeutics for people with rare diseases, who until then had been ‘orphaned’ by the medical and scientific community.
Read the full article here.